Lactose

Generic Name: Lactose

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂O_₁₁

CAS Number: 63-42-3

Unique Ingredient Identifier: 3SY5LH9PMK

Background: A disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

Indication: Not Available

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Hypothyroidism, Opioid Dependence, Thyroid Cancer

Associated Therapies: Maintenance treatment, opioids, Opioid Detoxification

Clinical Trials

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects

Phase 2

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Omeprazole
Drug: Rabeprazole
Drug: Lactose

First Posted Date: 2010-06-03

Last Posted Date: 2010-09-24

Lead Sponsor: Nantes University Hospital

Registration Number: NCT01136317

Locations: 🇫🇷
CHU de Nantes, Nantes, France

The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: lactose
Drug: Gabapentin 300mg
Drug: Gabapentin 600mg

First Posted Date: 2010-03-29

Last Posted Date: 2011-02-23

Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Target Recruit Count: 126

Registration Number: NCT01094925

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.

Phase 4

Completed

Conditions: Hepatic Encephalopathy

Interventions: Drug: Lactose
Drug: L-ornithine-L-aspartate

First Posted Date: 2010-01-01

Last Posted Date: 2021-05-10

Lead Sponsor: Centro Regional para el Estudio de las Enfermedades Digestivas

Target Recruit Count: 30

Registration Number: NCT01041755

Locations: 🇲🇽
Hospital Universitario "José Eleuterio González", Monterrey, Nuevo León, Mexico

The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial

Phase 2

Completed

Conditions: Chronic Fatigue Syndrome
Myalgic Encephalomyelitis

Interventions: Drug: Lactose capsula
Drug: Clonidine

First Posted Date: 2009-12-29

Last Posted Date: 2012-11-20

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 120

Registration Number: NCT01040429

Locations: 🇳🇴
Dept. of Pediatrics, Oslo University Hospital Rikshospitalet, Oslo, Norway

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

Not Applicable

Completed

Conditions: Urethral Sphincter Activity

Interventions: Drug: Lactose capsule
Drug: Pseudoephedrine
Drug: Solifenacin
Drug: Tamsulosin
Drug: Imipramine
Drug: Cyclobenzaprine

First Posted Date: 2009-12-09

Last Posted Date: 2012-06-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 56

Registration Number: NCT01028014

Locations: 🇺🇸
University of Alabama at Birmingham, The Kirklin Clinic, Birmingham, Alabama, United States

Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis

Not Applicable

Conditions: Calcific Tendonitis

Interventions: Drug: Colchicine
Drug: lactose

First Posted Date: 2009-09-23

Last Posted Date: 2010-07-20

Lead Sponsor: Bnai Zion Medical Center

Target Recruit Count: 80

Registration Number: NCT00983177

Locations: 🇮🇱
Bnai Zion Medical Center, Haifa, Israel

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Not Applicable

Terminated

Conditions: Myocardial Remodeling

Interventions: Drug: Eplerenone
Drug: Lactose Tablet

First Posted Date: 2009-09-18

Last Posted Date: 2014-03-28

Lead Sponsor: Creighton University

Target Recruit Count: 20

Registration Number: NCT00980031

Locations: 🇺🇸
Creighton University Medical Center (including ambulatory centers), Omaha, Nebraska, United States

Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin

Phase 3

Completed

Conditions: Diarrhoea

Interventions: Drug: Rifaximin
Drug: Lactose

First Posted Date: 2009-09-17

Last Posted Date: 2013-11-08

Lead Sponsor: Dr. Philipp Zanger, MD MSc DTM

Target Recruit Count: 258

Registration Number: NCT00979056

Locations: 🇩🇪
Institute of Tropical Medicine, University Hospital of Tübingen, Tübingen, Germany

Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine

Phase 2

Withdrawn

Conditions: Migraine

Interventions: Drug: BGC20-1531
Drug: Lactose

First Posted Date: 2009-04-28

Last Posted Date: 2022-06-03

Lead Sponsor: Boston Scientific Corporation

Registration Number: NCT00888680

Locations: 🇩🇰
Danish Headache Center, Glostrup, Denmark
🇬🇧
The City of London Migraine Clinic, London, United Kingdom
🇳🇴
Norwegian National Headache Centre, Trondheim, Norway

and more 1 locations

DAS181 Single Dose Escalation Study in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lactose
Drug: DAS181

First Posted Date: 2009-04-06

Last Posted Date: 2019-08-02

Lead Sponsor: Ansun Biopharma, Inc.

Target Recruit Count: 45

Registration Number: NCT00876161

Locations: 🇺🇸
Quintiles Phase One Services, Overland Park, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy